Quick Answer
CHINA PHARMA HOLDINGS, INC. reported Net Income Loss of -$4.74 million for the year ending 2024.
- CHINA PHARMA HOLDINGS, INC. showed a decrease of -53.8% in Net Income Loss from 2023 to 2024.
- This data is from CHINA PHARMA HOLDINGS, INC.'s annual report (Form 10-K), filed with the SEC on March 31, 2025.
- XBRL data for this metric is available from 2010 to 2024 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 15 years of available data (2010 to 2024), CHINA PHARMA HOLDINGS, INC.'s Net Income Loss has declined by 120.2%.
- Historical annual values: Fiscal year 2024: -$4.74 million | Fiscal year 2023: -$3.08 million | Fiscal year 2022: -$3.97 million | Fiscal year 2021: -$3.40 million | Fiscal year 2020: -$2.87 million | Fiscal year 2019: -$20.70 million | Fiscal year 2018: -$10.75 million | Fiscal year 2017: -$19.28 million | Fiscal year 2016: -$9.18 million | Fiscal year 2015: -$15.41 million | Fiscal year 2014: -$39.55 million | Fiscal year 2013: -$20.01 million | Fiscal year 2012: $4.62 million | Fiscal year 2011: $19.27 million | Fiscal year 2010: $23.41 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: